Fidelity Select Biotechnology
82 Devonshire St Boston MA 02109
Map
Phone: 800-544-8544
| Category: | Specialty-Health | | Fund Family: | Fidelity Investments | | Net Assets: | 1.41B | | Year-to-Date Return: | 11.20% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | 16-Dec-85 |
|
Rajiv Kaul
Lead Manager since
12-Oct-05 | | | Kaul is a portfolio manager with Fidelity Investments. Since joining Fidelity Investments in 1996, he has worked as a research analyst and portfolio manager. Kaul also manages another Fidelity fund. He is the recipient of the Kann Rasmusson Environment Award, the Deans Summer Research Award and a Ford Undergraduate Fellowship. |
| Min Initial Investment: | $2,500 | | Min Initial Investment, IRA: | $500 | | Min Initial Investment, AIP: | $2,500 | | Min Subsequent Investment: | $250 | | Min Subsequent Investment, IRA: | $100 | | Min Subsequent Investment, AIP: | $100 |
|
| |
| The investment seeks capital appreciation. The fund normally invests at least 80% of assets in securities ofcompanies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. These companies may include, companies involved in the research, development, or production of pharmaceuticals, including veterinary drugs. It may invest in securities of foreign issuers. The fund is nondiversified. |
| Last Dividend
(12-Apr-96):
| 0.03 | | Last Cap Gain
(7-Apr-00):
| 2.11 | | Annual Holdings Turnover
| 143.00% | | Average for Category:
| 101.53% |
|
| Expense | FBIOX | Category
Avg | | Total Expense Ratio: | 0.89%
| 1.67% | | Max 12b1 Fee: | 0.00%
| N/A | | Max Front End Sales Load: | 0.00%
| 5.30% | | Max Deferred Sales Load: | 0.00%
| 2.94% | | 3 Yr Expense Projection*: |
$284 | $721 | | 5 Yr Expense Projection*: |
$493 | $1,073 | | 10 Yr Expense Projection*: |
$1,096 | $2,092 |
|
|
0.93% Nasdaq 
0.62 (0.87%) 
Profile
